demonstrated that in NSCLC, TROP2 binds to IGF2R, promoting activation of the IGF2-IGF1R-Akt axis and thereby driving gefitinib resistance and TME remodeling (57). Here, TACSTD2 is linked to non-small cell lung carcinoma.